Lenvatinib capsules IP
Generic name: Lenvandr
Product name: Lenvatinib capsules IP
Preparation: Capsule
Specification: 250mg/30
Product
Lenvatinib, sold under the brand name Lenvandr among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).
In May 2016, the U.S. Food and Drug Administration (FDA) approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.
The drug is also approved in the US and in the European Union for hepatocellular carcinoma that cannot be removed surgically in patients who have not received cancer therapy by mouth or injection.
INDAR (INDAR) has launched more than 600 kinds of drugs, including conventional oral tablets, capsules, suspensions, eye drops and injectable biological products. Advanced production line, clean GMP plant and strict quality control have won GMP certification from drug regulatory authorities of many countries, including MHRA (British drug administration) and EU (European Union). Its products are exported to all parts of the world, including the UK, EU Member States and many developing countries.
